Last updated on September 2017

"A Phase III, randomized, double-blind, placebo-controlled study evaluating the efficacy and safety of copanlisib in combination with rituximab in patients with relapsed indolent B-cell non-Hodgkin’s lymphoma (iNHL) "


Other Details:

For more information, please contact:
844.229.3710
646.776.7532 (local)
Bayer@emergingmed.com

For Study Locations, Click Here



Find a site near you

Start Over

Research Center

Located in: Additional Locations, UT USA
2.85miles
  Connect »

Recruitment Status: Open


Brief Description Eligibility Contact Research Team


Volunteer Sign-up

Sign up for our FREE service to receive email notifications when clinical trials are posted in the medical category of interest to you.